SEC Form 4Coverage since May 28, 2026
$AVTX insider trading
Over the last 12 months, Avalo Therapeutics insiders reported no purchases and 4 sales totaling $150K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $150K 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $AVTX · 12Mvia TradingView
Top insiders · 12m
Doyle MittieChief Medical Officer4× · $150K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 1,000 | $20 | $20K | -1.9% | plan |
| Jun 30, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 4,654 | $20 | $93K | -8.2% | plan |
| Jun 23, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 1,450 | $18 | $26K | -2.7% | plan |
| May 28, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 679 | $16 | $11K | -1.4% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AVTX feed.